Zelluna ASA Logo

Zelluna ASA

Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.

ULTI | OL

Overview

Corporate Details

ISIN(s):
NO0010851603
LEI:
254900B4VALJZR9TL744
Country:
Norway
Address:
Ullernchausseen 64, 0379 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Zelluna ASA is a clinical-stage biopharmaceutical company focused on developing treatments for solid cancers. The company is pioneering a proprietary, allogeneic T-cell receptor-based Natural Killer (TCR-NK) cell therapy platform. This "off-the-shelf" approach merges the targeting capabilities of T-cell receptors with the therapeutic functions of NK cells to address significant unmet medical needs in oncology. Zelluna's mission is to deliver transformative, safe, and cost-efficient therapies with the potential to cure patients with advanced solid tumors.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-27 08:35
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 1.8 KB
2025-11-25 16:05
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 1.4 KB
2025-11-25 12:09
Major Shareholding Notification
ZELLUNA ASA: DISCLOSURE OF LARGE SHAREHOLDING
English 1.5 KB
2025-11-25 11:32
Post-Annual General Meeting Information
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025 - Attachm…
English 325.0 KB
2025-11-25 11:32
Post-Annual General Meeting Information
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025 - Attachm…
Norwegian 258.2 KB
2025-11-25 11:32
Post-Annual General Meeting Information
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025
English 1.5 KB
2025-11-04 13:04
Pre-Annual General Meeting Information
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025 - Atta…
Norwegian 1014.6 KB
2025-11-04 13:04
Pre-Annual General Meeting Information
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025
English 1.4 KB
2025-11-04 09:10
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 986 bytes
2025-11-04 08:28
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 1.2 KB
2025-11-04 07:29
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 2.1 KB
2025-11-04 07:00
Share Issue/Capital Change
Zelluna ASA - Ex. date
English 550 bytes
2025-11-04 00:58
Share Issue/Capital Change
Zelluna ASA - Key information relating to subsequent offering
English 2.8 KB
2025-11-04 00:35
Share Issue/Capital Change
Zelluna ASA - Mandatory notification of trade - Attachment: 20251104 - PDMR att…
English 219.0 KB
2025-11-04 00:35
Director's Dealing
Zelluna ASA - Mandatory notification of trade
English 703 bytes

Automate Your Workflow. Get a real-time feed of all Zelluna ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Zelluna ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Zelluna ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

bioMérieux Logo
Provides in vitro diagnostic solutions for clinical and industrial microbiology.
France
BIM
BiomX Inc. Logo
Develops phage therapies to target harmful bacteria in chronic diseases like cystic fibrosis.
United States of America
PHGE
BioNTech SE Logo
Pioneering mRNA immunotherapies and vaccines to combat cancer and infectious diseases.
United States of America
BNTX
BioPorto Logo
IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.
Denmark
BIOPOR
BioRestorative Therapies, Inc. Logo
A clinical-stage company developing stem cell therapies for pain, metabolic disorders, and aesthetics.
United States of America
BRTX
Biosergen AB Logo
Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.
Sweden
BIOSGN
Bio Solution Co.,Ltd. Logo
Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.
South Korea
086820
Biosynex Logo
European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.
France
ALBIO
BIO-TECHNE Corp Logo
Develops reagents and instruments for life sciences research and clinical diagnostic markets.
United States of America
TECH
biote Corp. Logo
Trains practitioners in hormone optimization using bioidentical pellets and nutraceuticals.
United States of America
BTMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.